SAN CARLOS, Calif.--(BUSINESS WIRE)--Sept. 18, 2006--Nektar Therapeutics (Nasdaq:NKTR) announced today that its Amphotericin B Inhalation Powder (ABIP) product has been granted orphan medicinal product designation by the European Commission for the prevention of pulmonary fungal infections in patients deemed at risk. This designation is based on a recommendation from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMEA).
